Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
TOKYO, Dec 2, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD). Etalanetug is designed to bind to the microtubule-binding region (MTBR) of tau protein and prevent the seeding and propagation of tau pathology.Anti-tau therapeutic antibody…
Read More
